Growth investors willing to take the risk to shoot for the moon find prime targets in the biotechnology sector. The “holy grail” of growth investors…

The more prevalent role that algorithms, automation and data have on our day to day existence, mean that the everyday person is more cogent than…

Amgen’s never moved faster. In late August of last year, the first patient enrolled in a small clinical study received treatment with a cancer drug…

It’s not surprising that Steven Yatomi-Clarke started his second career at a company named Prescient Therapeutics. In his first career as an investment banker, like…

The nation’s youngest cancer patients have been given new hope, with a cutting-edge treatment being brought to Australia.

Over the last decade, technological improvements and algorithmic learning have made rapid improvements to many facets of people’s lives. Smartphones can track daily routines and…

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The last earnings update…

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple…

Highlights: Innovative ‘basket’ study design will assess drug in multiple cancers Precision medicine approach offers a potentially faster development route International cancer expert Prof Miles…

Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company’s mainstream…